HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Current status of hormonal therapy of fibrocystic breast disease.

AuthorsL Dogliotti, P Fioretti, G B Melis, A Mussa, A Angeli
JournalAnnals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 464 Pg. 350-63 ( 1986) ISSN: 0077-8923 [Print] United States
PMID3089096 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Pregnadienes
  • Tamoxifen
  • Bromocriptine
  • Thyrotropin-Releasing Hormone
  • Sulpiride
  • Prolactin
  • Thyrotropin
  • Danazol
  • Lynestrenol
Topics
  • Bromocriptine (adverse effects, therapeutic use)
  • Chronobiology Phenomena
  • Danazol (adverse effects, therapeutic use)
  • Female
  • Fibrocystic Breast Disease (drug therapy)
  • Humans
  • Lynestrenol (adverse effects, therapeutic use)
  • Pregnadienes (therapeutic use)
  • Prolactin (blood)
  • Sulpiride
  • Tamoxifen (therapeutic use)
  • Thermography
  • Thyrotropin (blood)
  • Thyrotropin-Releasing Hormone
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: